China's Humanoid Robot Funding Exceeds 46 Billion Yuan as Mass Production Accelerates
N.R. Finch
Chinese robotics firms have raised over ¥46 billion since the start of 2026, surpassing all of 2025; Morgan Stanley has lifted its 2026 shipment forecast to over 50,000 units — capital and orders are now validating mass production in parallel.
Where is the money coming from — and going?
Per ITjuzi, total robotics funding in China has exceeded ¥46 billion year-to-date, already past full-year 2025. This means → capital is no longer just "bullish on the sector" — it is betting on production delivery.
AI² Robot recently raised close to ¥5 billion and plans a factory with annual capacity in the tens of thousands. Both AI² and X Square Robot have crossed ¥20 billion in valuation.
X Square Robot's backers include Alibaba, ByteDance, and Meituan. In plain terms = China's largest internet platforms are moving into physical AI collectively — this is not a niche VC play.
Can shipment data support the story?
Morgan Stanley raised its 2026 China humanoid-robot shipment forecast from 28,000 to over 50,000 units, and its 2030 estimate from 262,000 to 446,000. This means → a major Wall Street bank is confirming, in a published research note, that the demand curve is steepening.
Omdia data show global humanoid-robot shipments of roughly 13,000 units in 2025. All top five were Chinese companies.
Specifics: Unitree Robotics shipped over 5,500 units in 2025, beating expectations. Galbot (加速进化机器人) won an order worth roughly ¥236 million — about 500 robots — the largest single humanoid-robot purchase so far in 2026. UBTech's companion robot sold over 5,000 units within 20 days of launch.
An automaker crosses over — what is XPeng doing?
XPeng says it has entered early mass production and commercialization for humanoid robots.
Its "Iron" robot is slated to begin production before the end of 2026, initially deployed at XPeng car showrooms. In plain terms = the company is putting the robot to work in its own stores first — a real-world shakedown before broader rollout.
What is policy pushing?
China has launched a nationwide application-verification program requiring local governments and state-owned enterprises to complete robot testing in factory, warehouse, and healthcare settings within six months.
The goal is to finish verification and move select scenarios into routine operation by the end of 2026. This means → policy is not just offering subsidies — it is using administrative deadlines to force the accumulation of real operating data, closing the gap between "works in a demo" and "works on a shift."
How are capital markets and the supply chain following?
Unitree Robotics received approval in early June to list on the Shanghai Stock Exchange, targeting ¥4.2 billion in proceeds. This reflects a shift: leading players are moving from private funding rounds to public capital markets.
Hong Kong-listed Seer Intelligent Technology (仙工智能) says its products reach over 65 countries, but overseas revenue accounted for only about 18% of 2025 sales. The company flagged geopolitics and trade friction as key risks.
Morgan Stanley also raised its target price on precision-component supplier Lead Drive (领道驱动), citing rising parts demand driven by higher shipment volumes. In plain terms = when finished robots sell, component makers get paid first — supply-chain signals are more concrete than any assembler's slide deck.
Can this mass-production narrative actually land?
Funding past ¥46 billion, shipment forecasts doubling, a policy verification countdown — three threads are tightening at once, and the structural case for mass production is now assembled.
The real test comes down to two things: whether costs can fall to commercially sustainable levels, and whether reliability can survive real-world verification.
Put simply = the money is in place, the policy is in place, the orders exist. What remains is whether the robots, once they roll off the line, can actually do the job — and keep doing it. That is the final gate between "narrative" and "business."
Content is for reference only, not financial advice.